Accueil>>Signaling Pathways>> Immunology/Inflammation>> NOD-like Receptor (NLR)>>MCC7840 sodium

MCC7840 sodium (Synonyms: MCC7840 sodium)

Catalog No.GC62454

L'emlenoflast (MCC7840) sodium, une sulfonylurée, est un inhibiteur puissant et sélectif de l'inflammasome NLRP3, avec une IC50 <100 nM.

Products are for research use only. Not for human use. We do not sell to patients.

MCC7840 sodium Chemical Structure

Cas No.: 2380032-29-9

Taille Prix Stock Qté
5 mg
222,00 $US
En stock
10 mg
378,00 $US
En stock
25 mg
684,00 $US
En stock
50 mg
1 080,00 $US
En stock
100 mg
1 890,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

MCC7840 sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. MCC7840 sodium can be used for the research of inflammatory diseases[1][2].

MCC7840, a MCC950 analogue, shows useful activity in the inhibition of activation of the NLRP3 inflammasome, with an IC50 of <100 nM[1].

MCC7840 (4 mg/kg; i.v.) exhibits the half-life (3.39 h), AUC0-last (107097 ng•h/mL) and CL (0.621 mL/min/kg) in mice[2].MCC7840 (20 mg/kg; p.o.) exhibits the oral bioavailability (67.2%), Cmax (60467 ng/mL) and half-life (5.02 h) in mice[2].

[1]. El-Sharkawy LY, et, al. Inhibiting the NLRP3 Inflammasome. Molecules. 2020 Nov 25;25(23):5533.
[2]. O’neill L, et, al. Sulfonylureas and related compounds and use of same. WO2016131098A1.

Avis

Review for MCC7840 sodium

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for MCC7840 sodium

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.